Tatva Chintan Pharma Chem Limited has announced, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that an earnings call to discuss the financial results for the quarter and financial year ended March 31, 2026, is scheduled for Saturday, May 16, 2026. The call is set to commence at 5:00 p.m. IST and is being hosted by ICICI Securities. This announcement follows the company's previous intimation regarding a board meeting convened on the same date to consider and approve the audited financial results.

Board Meeting Agenda

The board meeting on May 16, 2026, will primarily focus on the company's financial performance for the fiscal year. The agenda includes the consideration and approval of the Standalone and Consolidated Audited Financial Results for the quarter and year ended March 31, 2026. Additionally, the board will consider recommending a final dividend on equity shares for FY26, subject to shareholder approval at the upcoming Annual General Meeting.

Earnings Call Details

The post-results conference call will be represented by key company officials, including Mr. Chintan Shah, Managing Director, and Mr. Ajesh Pillai, Chief Financial Officer. The event provides a platform for the management to discuss the financial performance and outlook with investors and analysts. ICICI Securities has provided a Diamond Pass registration link for participants wishing to join the session.

Trading Window Closure

In compliance with the Company's Code of Conduct for Prohibition of Insider Trading, the trading window for designated persons was closed effective April 1, 2026. This closure will remain in effect until the expiry of 48 hours from the date the financial results are made public to the stock exchanges. The intimation regarding these schedules has been filed with BSE Limited and the National Stock Exchange of India Limited.

Tatva chintan pharma Chem Limited has formally notified stock exchanges that it does not qualify as a Large Corporate under the Securities and Exchange Board of India's debt securities framework. The confirmation was submitted to both BSE Limited and National Stock Exchange of India Limited on April 29, 2026.

Regulatory Compliance and Framework

The disclosure was made pursuant to SEBI Master Circular SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated October 15, 2025, read with Chapter XII of SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, and SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. These regulations govern fund raising by issuance of debt securities by Large Corporates and require entities to make initial disclosures within 30 days from the beginning of the financial year.

Financial Position and Credit Profile

As part of the mandatory disclosure requirements, Tatva Chintan Pharma Chem provided detailed information about its financial standing and creditworthiness:

The company's outstanding borrowing of Rs. 6.04 crores as of March 31, 2026, falls below the threshold criteria that would classify it as a Large Corporate under the SEBI framework. The credit ratings assigned by CRISIL Ratings Limited reflect the company's creditworthiness, with BBB+/Stable indicating adequate safety for long-term obligations and A2 representing good safety for short-term obligations.

Regulatory Implications

By confirming its non-Large Corporate status, Tatva Chintan Pharma Chem is exempt from the mandatory borrowing requirements through debt securities that apply to Large Corporates. The SEBI framework requires Large Corporates to raise a specified portion of their incremental borrowings through debt securities markets rather than traditional bank loans.

The disclosure was signed by Company Secretary and Compliance Officer Ishwar Nayi and Chief Financial Officer Ajesh Pillai, ensuring proper authorization and compliance with regulatory requirements. This confirmation allows the company to continue its current financing structure without the additional compliance obligations imposed on Large Corporates under the SEBI debt securities framework.